Health ❯ Healthcare

Drug Safety

Adverse Effects Adverse Reactions Side Effects Adverse Events Regulatory Actions Contamination Opioids Food Supply Safety Counterfeit Medications Inspection Processes

Edgewise Reports Favorable Interim Safety in Phase 2 HCM Trial of EDG-7500

The readout underscores a clean cardiac safety profile, preserving the timeline for full Part D data in Q2 2026.

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Dyne’s DMD Drug Hits Primary Endpoint in DELIVER REC, Shows Functional Gains

FDA Grants Full Approval to Jaypirca for Relapsed CLL/SLL After Covalent BTK Therapy

Bayer Stroke Drug Asundexian Hits Phase III Goals, Shares Jump

FDA Approves Komzifti, First Menin Inhibitor for Relapsed NPM1‑Mutant AML

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer

FDA Approves Darzalex Faspro as First Therapy for High-Risk Smoldering Multiple Myeloma

FDA Approves Lynkuet, a Nonhormonal Pill for Menopausal Hot Flashes

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Phase 3 Trial Finds Tukysa Improves PFS in First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

Kerala Bans Sresan Medicines After TN Cancels Licence, Halts Substandard Respifresh TR